Drug treatment of chemotherapy-induced delayed emesis

Drugs

Volumn 52, Issue 5, 1996, Pages 639-648

  Tavorath, Ranjana ^a   Hesketh, Paul J ^a  

^a ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOLASETRON MESILATE; GRANISETRON; LORAZEPAM; METOCLOPRAMIDE; NEUROKININ 1 RECEPTOR; ONDANSETRON; SEROTONIN 3 ANTAGONIST; SUBSTANCE P; TROPISETRON;

CLINICAL TRIAL; DISEASE CONTROL; DRUG EFFICACY; EXTRAPYRAMIDAL SYNDROME; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MEDICAL RESEARCH; META ANALYSIS; NAUSEA; NONHUMAN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; RECEPTOR BLOCKING; REVIEW; VOMITING;

EMESIS;

EID: 0029799049     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199652050-00002     Document Type: Review

References (43)

1. Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N Engl J Med 1993; 329: 1790-6
2. 3 receptor antagonists. Support Care Cancer 1994; 2: 286-92
3. Kris MG, Gralla RJ, Clark RA, et al. Incidence, course and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985; 3 (10): 1379-84
4. Martin M, Diaz-Rubio E, Sanchez A, et al. The natural course of carboplatin-induced emesis. Acta Oncologica 1990; 29: 593-5
5. Fetting JH, Grochow LB, Folstein MF, et al. The course of nausea and vomiting after high-dose cyclophosphamide. Cancer Treat Rev 1982; 66: 1487-93
6. Gralla RJ, Itri LM, Pisko SE, et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981; 305: 905-9
7. Martin M. Pattern of emesis with various chemotherapeutic agents. Support Care Cancer. In press
8. Kris MG, Gralla RH, Tyson LB, et al. Controlling delayed vomiting: double-blind randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989; 7: 108-14
9. Gandara DR, Harvey WH, Monaghan GG, et al. The delayed emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. Semin Oncol 1992 Aug; 19 (4 Suppl. 10): 67-71
10. Passalacqua R, Cocconi G, Bella M, et al. Double-blind, randomized trial for the control of delayed emesis in patients receiving cisplatin: comparison of placebo vs. adrenocorticotropic hormone (ACTH). Ann Oncol 1992; 3: 481-5
11. Roila F, Boschetti E, Tonato M, et al. Predictive factors of delayed emesis in cisplatin-treated patients and tolerability of metoclopramide or dexamethasone. Am J Clin Oncol Cancer Clin Trials 1991; 14 (3): 238-42
12. Shinkai T, Saijo N, Eguchi K, et al. Control of cisplatin-induced delayed emesis with metoclopramide and dexamethasone: a randomized controlled trial. Jpn J Clin Oncol 1989; 19 (1): 40-4
13. Florczyk AP, Schurig JE, Bradner WT, et al. Cisplatin-induced emesis in the ferret: a new animal model. Cancer Treat Rev 1982; 66: 187-9
14. Neuwelt EA, Glasberg M, Frankel E. Neurotoxicity of chemotherapeutic agents after blood-brain barrier modification: neuropathologic studies. Ann Neurol 1983; 14: 316-24
15. Cunningham D, Morgan RJ, Mills PR, et al. Functional and structural changes of the human proximal small intestine after cytotoxic therapy. J Clin Pathol 1985; 38: 265-70
16. Allan SG, Smythe JF. Small intestinal mucosal toxicity of cisplatinum: comparison of toxicity with platinum analogues and dexamethasone. Br J Cancer 1986. 53: 355-60
17. Aapro MS, Alberts DS. High-dose dexamethasone for prevention of cisplatin-induced vomiting. Cancer Chemother Pharmacol 1981; 7: 11-4
18. Strum S, McDermed J, Abrahano-Umali R, et al. Management of cisplatin (DDP) induced delayed onset nausea and vomiting: preliminary results with 2 drug regimens. Proc Am Soc Clin Oncol 1985; 4: 263
19. Clark R, Kris M, Tyson L, et al. Antiemetic trials to control delayed vomiting following high-dose cisplatin [abstract]. Proc Am Soc Clin Oncol 1986; 5: 257
20. 3 receptor antagonists injected into AP inhibit cisplatin induced emesis in ferrets. Br J Pharmacol 1989; 97: 247-55
21. 3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. Cancer 1994; 73: 445-54
22. Hesketh PJ, Navari R, Grote T, et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis. J Clin Oncol 1996; 14 (8): 2242-9
23. Kris MG, Tyson LB, Clark RA, et al. Oral ondansetron for the control of delayed emesis after cisplatin: report of a phase II study and a review of completed trials to manage delayed emesis. Cancer 1992: 70: 1012-6
24. Roila F, Bracarda S, Tonato M, et al. Ondansetron (GR 38032) in the prophylaxis of acute and delayed cisplatin-induced emesis. Clin Oncol 1990; 2: 268-72
25. DeMulder PHM, Seynaeve C, Vermorken JB, et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting: a multicenter randomized double-blind crossover study. Ann Intern Med 1990; 113: 834-40
26. Navari R, Madajewicz S, Anderson N, et al. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol 1995; 13 (9): 2408-16
27. Johnston D, Latreille J, Laberge F, et al. Preventing nausea and vomiting during days 2-7 following high dose cisplatin chemotherapy. A study by the National Cancer Institute of Canada Clinical Trials Group [abstract]. Proc Am Soc Clin Oncol 1995; 14: 529
28. Roila F, De Angelis V, Contu A, et al. Ondansetron vs metoclopramide both combined with dexamethasone in the prevention of cisplatin-induced delayed emesis [abstract]. Proc Am Soc Clin Oncol 1996; 15: 528
29. Schmoll HJ. The role of ondansetron in the treatment of emesis induced by non-cisplatin containing chemotherapy regimens. Eur J Clin Oncol 1989; 25 Suppl. 1: S35-9
30. Bonneterre J, Chevallier B, Metz R, et al. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. J Clin Oncol 1990; 8: 1063-9
31. Kaasa S, Kvaloy S, Dicato MA, et al. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. Eur J Cancer 1990; 26 (3): 311-4
32. Marscher NW, Adler M, Nagel GA, et al. Double-blind randomized trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. Eur J Cancer 1991; 27 (9): 1137-40
33. Soukop M, McQuade B, Hunter E, et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology 1992; 49: 295-304
34. Jones AL, Hill AS, Soukop M, et al. Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 1991; 338: 483-7
35. Koo WH, Ang PT. Randomized control study to evaluate the role of oral dexamethasone in prevention of chemotherapy-induced delayed emesis [abstract]. Proc Am Soc Clin Oncol 1995; 14: 531
36. Kaizer L, Warr D, Hoskins P, et al. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994; 12 (5): 1050-7
37. Perez E. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol 1995; 13 (4): 1036-43
38. Italian Group for Antiemetic Research. Dexamethasone, granisetron or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995; 332 (1): 1-5
39. Smith-Kline Beecham Internal Report: MY-1022/BRL 043694/1/CP MS-288, King of Prussia, Pennsylvania, USA
40. 3 antagonists to dexamethasone after twenty four hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy [abstract]. Support Care Cancer 1995; 3: 339
41. Rittenberg CN, Gralla RJ, Lettow LA, et al. New approaches in preventing delayed emesis: altering the time of regimen initiation and use of combination therapy in a 109 patient trial. Proc Am Soc Clin Oncol 1995; 14: 526
42. Nakanishi S. Mammalian tachykinin receptors. Annu Rev Neurosci 1991; 14: 123-36
43. 1) receptor antagonist, CP-99994, in ferrets. Eur J Pharmacol 1993; 3-4